RHY Rhythm Biosciences Limited
Healthcare · Diagnostics & Research
· website
$0.08
52wk 0.07 – 0.28
Overall
26.2
Value
45.5
Growth
0.0
Health
69.2
Quality
0.0
Momentum
4.5
Dividend
—
Price
About Rhythm Biosciences Limited
Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.
Price analytics
Returns
| 1 day | -1.2% |
| 1 week | -2.4% |
| 1 month | -5.9% |
| 3 months | -14.0% |
| 6 months | -57.9% |
| 1 year | -10.1% |
| 3 years | -75.0% |
Risk
| Volatility (1y ann.) | 105.6% |
| Beta vs ASX 200 | 1.99 |
| Sharpe (1y) | 0.37 |
| VaR 95% (1-day) | -9.1% |
| Max drawdown (1y) | -69.6% |
| Off 1-year high | -68.6% |
Technicals
| RSI(14) | 40 |
| vs 50DMA | -6.2% |
| vs 200DMA | -40.4% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
45.5
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
4.5
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
19
Position in 52-week range
2
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$28.31M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
0.43
EV / EBITDA
-4.43
Price / Book
8.00
ROE
-276.0%
Operating margin
-3,067.5%
Net margin
0.0%
Total cash
$3.44M
Total debt
$247,980
Current ratio
3.60
Debt / Equity
0.07
Free cash flow
$-3.29M
Avg volume
213,600
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$85.34K
- Gross profit-$274.62K
- Operating income-$7.46M
- Net income-$5.93M
- Diluted EPS-0.02
- Free cash flow-$5.26M
- Net debt-$3.11M